Pfizer leads top-selling pharma forecast — Evaluate report
Pfizer upped its 2022 Covid vaccine guidance by $2 billion last quarter on the heels of its bivalent booster launch. While we’ve yet to see the full-year figures, Evaluate expects the good fortune will continue into this year.
The pharma giant made the top of Evaluate’s projected list of top-selling pharma companies in 2023, with a forecast of more than $70 billion in prescription drug sales. The company made a record $81 billion in 2021, and $22.6 billion in Q3 of last year alone. Despite slow booster uptake in the US — just over 15% of Americans 5 years and older have rolled up their sleeves — Evaluate predicts that Comirnaty and Paxlovid sales will make Pfizer a top earner next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.